TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7995001

Group type: EXPERIMENTAL
Intervention: 400 mg ketoconazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched placebo (control phase)
Number of subjects: 9
Study: 2691002

Group type: EXPERIMENTAL
Intervention: 2.5% glucose + glucose polymer (group G + GP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2.5% glucose (group G)
Number of subjects: 18
Study: 812895

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium powder, 20 mg three times daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium powder
Number of subjects: 26
Study: 31713269

Group type: EXPERIMENTAL
Intervention: QUICK-STOP stopping rule applied to randomized tests
Number of subjects: 0
Study: 30865071

Group type: EXPERIMENTAL
Intervention: CO2 laser lash tilt technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Upper eyelid blepharoplasty alone (control)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of laser lash group vs control group
Number of subjects: 46
Study: 28954261

Group type: COMPARATOR
Intervention: Supervised Toothbrushing (STB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) with High-Viscosity Glass-Ionomer Cement (HVGIC) sealants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Composite Resin (CR)
Number of subjects: 120
Study: 26421970

Group type: EXPERIMENTAL
Intervention: Male version case histories
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Female version case histories
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nonambiguous case histories
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ambiguous case histories
Number of subjects: 180
Study: 24968210

Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs)
Number of subjects: 28
Study: 22615291

Group type: EXPERIMENTAL
Intervention: Tablet A (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tablet B (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsule (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral suspension (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All formulations of posaconazole (100 mg)
Number of subjects: 16
Study: 19278796

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 32
Study: 17433383

Group type: EXPERIMENTAL
Intervention: Vision Restoration Therapy (VRT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Training-related hallucinations
Number of subjects: 140
Study: 15333726

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting adequate complementary feeding practices; health and nutrition workers trained to counsel on locally developed feeding recommendations.
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting adequate complementary feeding practices.
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Control group with no specific feeding intervention.
Number of subjects: 1025
Study: 12555626

Group type: EXPERIMENTAL
Intervention: Transdermal 10 mg nitroglycerine patch (12 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Long-acting oral 40 mg isosorbide-5-mononitrate (once a day)
Number of subjects: 150
Study: 9792489

Group type: EXPERIMENTAL
Intervention: exercise plus relaxation
Number of subjects: 76

Group type: COMPARATOR
Intervention: exercise without relaxation
Number of subjects: 76
Study: 7758297

Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Positive life events
Number of subjects: 1360
Study: 2195921

Group type: COMPARATOR
Intervention: Combination methylprednisolone and placebo troleandomycin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prednisone and troleandomycin (P-TAO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylprednisolone-TAO (MPn-TAO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Troleandomycin (250 mg once daily or every other day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Troleandomycin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-dose TAO combined with MPn
Number of subjects: 15
Study: 391624

Group type: EXPERIMENTAL
Intervention: Cinnarizine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31896379

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 731
Study: 29951850

Group type: EXPERIMENTAL
Intervention: Physical exercise (n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Occupational therapy (n = 20)
Number of subjects: 38
Study: 28318365

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE) using Embosphere microspheres
Number of subjects: 128

Group type: COMPARATOR
Intervention: Panhysterectomy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy subjects (control group for TGF-β levels)
Number of subjects: 128
Study: 25491384

Group type: EXPERIMENTAL
Intervention: Allergic women
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-allergic women
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Increased CCL22 mRNA expression in CBMC
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: p35 expression in placenta
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IL-5 expression in PBMC
Number of subjects: 19
Study: 24785602

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 143

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 143
Study: 23116646

Group type: EXPERIMENTAL
Intervention: GLAR+MET+1-3×GLU (group 2)
Number of subjects: 476

Group type: COMPARATOR
Intervention: GLAR+MET+3×GLU (group 1)
Number of subjects: 476

Group type: COMPARATOR
Intervention: GLAR+MET+IS+1-3×GLU (group 3)
Number of subjects: 476
Study: 19458319

Group type: EXPERIMENTAL
Intervention: High-intensity CIMT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dose-matched CIMT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional UE therapy (Control)
Number of subjects: 52
Study: 17877827

Group type: COMPARATOR
Intervention: Room temperature irrigation and intravenous fluids
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid at 38 degrees C and room temperature intravenous fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid and warmed intravenous fluids at 38 degrees C
Number of subjects: 120
Study: 14687858

Group type: EXPERIMENTAL
Intervention: sertraline (50‐200 mg/day)
Number of subjects: 239

Group type: COMPARATOR
Intervention: imipramine (75‐225 mg/day)
Number of subjects: 239
Study: 12109659

Group type: EXPERIMENTAL
Intervention: Very-high-flow injection-rate method (group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional injection-rate method (group B)
Number of subjects: 240
Study: 9433339

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8948688

Group type: EXPERIMENTAL
Intervention: Nifedipine (average daily dose, 21.5 mg/day) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 24
Study: 1632260

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo b.i.d.
Number of subjects: 20
Study: 79031

Group type: EXPERIMENTAL
Intervention: Oral linoleic-acid supplementation for 10 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo lipid
Number of subjects: 12
Study: 30934797

Group type: EXPERIMENTAL
Intervention: 5 g PGX granules (PGXG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4.5 g PolyGlycopleX softgel capsules (PGXS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 g rice flour (RF)
Number of subjects: 120
Study: 29556618

Group type: EXPERIMENTAL
Intervention: Fluorescent hexylaminolevulinate photodynamic diagnosis (PDD)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard white-light cystoscopy (WLC)
Number of subjects: 113
Study: 26070406

Group type: EXPERIMENTAL
Intervention: Paritaprevir plus ritonavir (200/100 mg), ombitasvir (25 mg), and dasabuvir (400 mg)
Number of subjects: 24
Study: 24107882

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study: 21806904

Group type: EXPERIMENTAL
Intervention: Parental presence during dental treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: No parental presence during dental treatment
Number of subjects: 90
Study: 19014944

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: White-light imaging
Number of subjects: 1256
Study: 16505424

Group type: EXPERIMENTAL
Intervention: Shorter time between the first day of chemotherapy and the last day of chest radiation (SER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter SER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Each week of extension of the SER beyond the shortest SER arm
Number of subjects: 0
Study: 17145253

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg, sustained-release)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 12689614

Group type: EXPERIMENTAL
Intervention: FR+ Stress Group (familial risk)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FR‐ Stress Group (normal risk)
Number of subjects: 53

Group type: COMPARATOR
Intervention: FR‐ Control Group (normal risk, no stress)
Number of subjects: 53
Study: 9884376

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 317

Group type: COMPARATOR
Intervention: Multivitamins
Number of subjects: 317

Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 8905472

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min) before and after testosterone replacement (250 mg i.m. every 21 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min) before and after testosterone replacement
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms po at 0 min)
Number of subjects: 14
Study: 1713132

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6344041

Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 1300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29521681

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 41
Study: 27632641

Group type: EXPERIMENTAL
Intervention: 2-year foot abduction bracing
Number of subjects: 139

Group type: COMPARATOR
Intervention: 4-year foot abduction bracing
Number of subjects: 139
Study: 25075811

Group type: EXPERIMENTAL
Intervention: Lower awareness rating at 12 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lower awareness rating at 36 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Higher awareness rating at 12 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Higher awareness rating at 36 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: NPI-Q score increase for lower awareness at 36 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: MMSE score decline for lower awareness at 36 months
Number of subjects: 95
Study: 23294420

Group type: EXPERIMENTAL
Intervention: 3400 m altitude (first/second night) - males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3400 m altitude (first/second night) - females
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude (first night) - males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude (first night) - females
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude (after 10 days) - males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude (after 10 days) - females
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3400 m altitude - males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude - males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5400 m altitude - females
Number of subjects: 37
Study: 21401764

Group type: EXPERIMENTAL
Intervention: Practice nurse intervention group
Number of subjects: 230

Group type: COMPARATOR
Intervention: General practitioner control group
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 230
Study: 18416823

Group type: EXPERIMENTAL
Intervention: RAISIN (1 cup raisins/d)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WALK (increased steps walked/d)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RAISINS + WALK (combination of both interventions)
Number of subjects: 34
Study: 17041169

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 15581120

Group type: EXPERIMENTAL
Intervention: Low-load condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-load condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-load condition preceded by high-load trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-load and low-load conditions mixed
Number of subjects: 0
Study: 11084177

Group type: EXPERIMENTAL
Intervention: Triphasic norgestimate-ethinyl E2
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 9487836

Group type: EXPERIMENTAL
Intervention: 20% sodium bicarbonate dentifrice, 1.5% hydrogen peroxide solution, mouth moisturizer
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Crest dentifrice, Toothette Plus with hydrogen peroxide solution, mouth moisturizer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Crest dentifrice, Toothette Plus with control solution, no mouth moisturizer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Crest dentifrice, Toothette without baking soda, control solution, no mouth moisturizer
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Crest dentifrice, Toothette saturated with 1.5% flavored H2O2, no mouth moisturizer
Number of subjects: 150
Study: 8376833

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3019910

Group type: EXPERIMENTAL
Intervention: Nylon waist cord worn throughout the follow-up period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subjects who cut off the cord
Number of subjects: 40
Study: 30407961

Group type: EXPERIMENTAL
Intervention: Simulation-based AACT training for postpartum nurses
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simulation-based I-PASS education for control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simulation-based AACT training for labor and delivery nurses
Number of subjects: 70
Study: 27649413

Group type: EXPERIMENTAL
Intervention: Perception training with duration-equalized English vowels
Number of subjects: 34

Group type: COMPARATOR
Intervention: Watching English videos (Control)
Number of subjects: 34
Study: 24886787

Group type: EXPERIMENTAL
Intervention: Off-pump CABG surgery (n=1472)
Number of subjects: 2932

Group type: COMPARATOR
Intervention: On-pump CABG surgery (n=1460)
Number of subjects: 2932
Study: 21798891

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4853

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4853
Study: 20683611

Group type: EXPERIMENTAL
Intervention: Isometric training (4 × 20 s contractions at 80% of maximum voluntary plantarflexion moment, three times per week for 8 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isometric training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Change in TST K
Number of subjects: 12
Study: 19071991

Group type: EXPERIMENTAL
Intervention: Affective priming of naming responses without stimulus repetition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective priming of naming responses with varying number of stimulus presentations
Number of subjects: 0
Study: 16161944

Group type: COMPARATOR
Intervention: Statin treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Statin-naive patients
Number of subjects: 112
Study: 12748132

Group type: EXPERIMENTAL
Intervention: Single subacromial injection of methylprednisolone with bupivicaine (group S, n=54)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bupivicaine only (group C, n=44)
Number of subjects: 98
Study: 11076414

Group type: EXPERIMENTAL
Intervention: Pumpan (homeopathic compound)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 49
Study: 8641404

Group type: EXPERIMENTAL
Intervention: rhG‐CSF primed PBSCT
Number of subjects: 17

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: rhG‐CSF mobilized PBSCT
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PBSCT mobilized solely using rhG‐CSF
Number of subjects: 17
Study: 2071888

Group type: EXPERIMENTAL
Intervention: 3 x 10 mg doses of vinpocetine
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 3 x 20 mg doses of vinpocetine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 6827767

Group type: EXPERIMENTAL
Intervention: Night urinary sodium excretion estimated by quantitative chloride titrator strips
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Qualitative chloride titrator applied every other day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Three 24-hour urine collections
Number of subjects: 3
Study: 31427345

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan injection
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 136
Study: 29615090

Group type: EXPERIMENTAL
Intervention: InSciEd Out program - school-based anti-stigma intervention in mental health
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teacher narratives
Number of subjects: 0
Study: 27821083

Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT) using yttrium‐90 resin microspheres (SIR‐Spheres®)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Continuous oral Sorafenib (Nexavar®) at a dose of 400 mg twice daily
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Continuous oral Sorafenib (Nexavar®)
Number of subjects: 360
Study: 24786605

Group type: EXPERIMENTAL
Intervention: Diabetes history (n=62)
Number of subjects: 504

Group type: COMPARATOR
Intervention: No diabetes history (n=442)
Number of subjects: 504
Study: 22678846

Group type: EXPERIMENTAL
Intervention: 3D TOF-MRA at 3T
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3D TOF-MRA at 1.5T
Number of subjects: 96

Group type: COMPARATOR
Intervention: DSA (reference standard)
Number of subjects: 96
Study: 19217229

Group type: EXPERIMENTAL
Intervention: Risperidone (0.125-2mg/d) for 6 months
Number of subjects: 12
Study: 18591574

Group type: EXPERIMENTAL
Intervention: Aripiprazole (mean dose approximately 9 mg/day at endpoint; range = 0.7‐15.0 mg)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 15836940

Group type: EXPERIMENTAL
Intervention: Orthosis applied to the case group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Not applicable (correlation analysis)
Number of subjects: 29
Study: 12027240

Group type: EXPERIMENTAL
Intervention: Strengths model of case management (SCM)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study: 8771941

Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg (original manufacturer)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg (locally produced)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 399
Study: 1729865

Group type: EXPERIMENTAL
Intervention: Upright cycle ergometry
Number of subjects: 14

Group type: COMPARATOR
Intervention: Recumbent cycle ergometry
Number of subjects: 14
Study: 6418371

Group type: EXPERIMENTAL
Intervention: FA plus methyl‐CCNU (FAMe)
Number of subjects: 241

Group type: COMPARATOR
Intervention: 5‐fluorouracil plus Adriamycin (FA)
Number of subjects: 241

Group type: COMPARATOR
Intervention: FA plus mitomycin C (FAMi)
Number of subjects: 241
Study: 30428828

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (MIC test)
Number of subjects: 144
Study: 24924603

Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium hydrogel patch (LX‐P)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Loxoprofen sodium tablet (LX‐T)
Number of subjects: 169
Study: 25201893

Group type: EXPERIMENTAL
Intervention: OMNIHEART-like nutrient profile
Number of subjects: 2195

Group type: COMPARATOR
Intervention: Control (typical American nutrient profile)
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: OMNIHEART score higher by 1 point
Number of subjects: 2195
Study: 22292152

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 0
Study: 20628238

Group type: EXPERIMENTAL
Intervention: Infliximab treatment for 1 year
Number of subjects: 186